Donsumab associated with bone density increase and clinical improvement in a long-term hemodialysis patient. Case report and review of the literature

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F14%3A00059141" target="_blank" >RIV/00023001:_____/14:00059141 - isvavai.cz</a>

Výsledek na webu

<a href="http://orbis.lfhk.cuni.cz/Acta_Medica/2014/2014_30.pdf" target="_blank" >http://orbis.lfhk.cuni.cz/Acta_Medica/2014/2014_30.pdf</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Donsumab associated with bone density increase and clinical improvement in a long-term hemodialysis patient. Case report and review of the literature

Popis výsledku v původním jazyce

Denosumab is a full length human monoclonal antibody binding to the receptor activator of nuclear factor kappa-B ligand (RANKL), mimicking the action of osteoprotegerin (OPG, natural decoy receptor of RANKL) and representing a novel therapy of osteoporosis, approved by FDA in 2010 (1). By its action on RANKL, denosumab reduces the signal that is essential for osteoclasts formation, maturation, function and survival. RANKL inhibition has no effect on osteoblasts. Denosumab is not cleared by the kidneys.In chronic kidney disease (CKD) dose adjustment of denosumab is not required but calcium and vitamin D supplementation is strongly recommended (2). So far, only few case reports or very limited case series describing the experience with denosumab in CKDhave been published. They all stopped the therapy after single dose because of hypocalcemia (3, 4, 5, 6, 7, 8) (Table 1). We present a case of successful treatment of osteoporosis in a young hemodialysis patient with repeated denosumab do

Název v anglickém jazyce

Donsumab associated with bone density increase and clinical improvement in a long-term hemodialysis patient. Case report and review of the literature

Popis výsledku anglicky

Denosumab is a full length human monoclonal antibody binding to the receptor activator of nuclear factor kappa-B ligand (RANKL), mimicking the action of osteoprotegerin (OPG, natural decoy receptor of RANKL) and representing a novel therapy of osteoporosis, approved by FDA in 2010 (1). By its action on RANKL, denosumab reduces the signal that is essential for osteoclasts formation, maturation, function and survival. RANKL inhibition has no effect on osteoblasts. Denosumab is not cleared by the kidneys.In chronic kidney disease (CKD) dose adjustment of denosumab is not required but calcium and vitamin D supplementation is strongly recommended (2). So far, only few case reports or very limited case series describing the experience with denosumab in CKDhave been published. They all stopped the therapy after single dose because of hypocalcemia (3, 4, 5, 6, 7, 8) (Table 1). We present a case of successful treatment of osteoporosis in a young hemodialysis patient with repeated denosumab do

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FE - Ostatní obory vnitřního lékařství

OECD FORD obor

—

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2014

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Acta medica

ISSN

1211-4286

e-ISSN

—

Svazek periodika

57

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

5

Strana od-do

30-34

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—